GlassScriptPhysician profile
Edward J Block
NPI 1811973860
$32,303.09
in general payments reported to CMS, 2019-2025
39 companies · $4,154 in 2025
The $4,154 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $259 · 2021: $142 · 2022: $2,326 · 2023: $2,936 · 2024: $3,337 · 2025: $4,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $14.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,413.05 |
| Education | $14.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $17,812.00 | 2019 | |
| Abbvie INC. | $5,416.38 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,375.06 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,284.31 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,038.94 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $731.88 | 2019-2025 | |
| Genzyme Corporation | $710.27 | 2022-2025 | |
| Celgene Corporation | $557.59 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $426.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $319.45 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $265.16 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $243.16 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $185.65 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $169.61 | 2019-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $167.05 | 2024-2025 | Voquezna |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $159.44 | 2022-2025 | Dupixent |
| Allergan, INC. | $151.41 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $144.60 | 2022 | |
| Braintree Laboratories, INC. | $138.83 | 2022-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $130.92 | 2022-2025 | Rebyota, Clenpiq |
| Daiichi Sankyo INC. | $123.05 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $102.99 | 2022-2025 | Linzess |
| Vivus LLC | $85.07 | 2019-2025 | Qsymia, Pancreaze |
| Merck Sharp & Dohme LLC | $82.42 | 2019-2020 | |
| Exact Sciences Corporation | $63.36 | 2025 | Cologuard Collection Kit |
| Celltrion USA INC. | $60.21 | 2024-2025 | Zymfentra, Vegzelma |
| Medtronic, INC. | $51.54 | 2022-2024 | Nexpowder |
| Redhill Biopharma INC. | $39.58 | 2022-2023 | Talicia |
| Albireo Pharma, INC. | $35.78 | 2024 | Iqirvo |
| Shionogi INC | $31.60 | 2019 | |
| Fresenius Kabi USA, LLC | $31.17 | 2025 | |
| Boston Scientific Corporation | $28.14 | 2024 | |
| Biocon Biologics INC | $27.34 | 2025 | Hulio |
| Novo Nordisk INC | $24.41 | 2025 | Wegovy |
| Alcresta Therapeutics, INC. | $22.04 | 2024 | Relizorb |
| Alfasigma USA, INC. | $21.01 | 2022 | |
| W. L. Gore & Associates, INC. | $19.07 | 2020 | |
| Dova Pharmaceuticals | $13.15 | 2019 | |
| Qol Medical, LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.